Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elucirem (gadopiclenol) in DSC-MRI perfusion of brain gliomas
NCT06057168Phase 3Completed
- Sponsor
- Guerbet
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of gadopiclenol (2 arms), sponsored by Guerbet. Primary endpoint: Diagnostic Quality of Cerebral Blood Volume Map of Dynamic Susceptibility Contrast MRI Perfusion. Started Sep 2023; status: completed.
02
Drugs
gadopiclenol
Beyond the preview
Go deeper on NCT06057168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057168.